首页 > 最新文献

Journal of Pharmaceutical Policy and Practice最新文献

英文 中文
'Challenges in pediatric medicine access in Albania: insights from community Pharmacists'. “阿尔巴尼亚儿科医学准入的挑战:来自社区药剂师的见解”。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2521425
E Petro, T Martopullo, A K Mantel-Teeuwisse, H A van den Ham, F Suleman

Background: Medicines are crucial for strengthening health systems and building patient confidence. Yet, there is a global shortage of age-appropriate pediatric formulations, particularly in low- and middle-income countries. Pharmacists are vital in ensuring pediatric medicines' availability and proper use. Research has often overlooked pediatric needs, resulting in significant gaps in understanding the accessibility of medicines for children. This research therefore sought to identify the barriers and facilitators to accessing pediatric medicines from the perspective of community pharmacists in Albania.

Methods: Semi-structured interviews were conducted in March 2024 with 18 members of the Albanian Order of Pharmacists, working in the six most populated cities in Albania. Interviews were transcribed verbatim and analyzed using the Pharmaceutical Value Chain framework.

Results: Barriers to accessing pediatric medicines were evident in almost all domains of the Pharmaceutical Value Chain framework except for health information technology, a domain not referred to by participants. Issues addressed included a limited number of items on the reimbursement list for different child-specific diagnoses and occasional stock-outs of child-appropriate medicines. Open communication channels with other healthcare professionals and patient education were identified as key facilitators in improving access to pediatric medicines.

Conclusion: This is the first study to examine pediatric medicine access in Albania from the viewpoint of community pharmacists. The findings provide context-specific insights that can inform policy reforms and health system strategies to improve the equitable availability of pediatric medicines.

背景:药物对于加强卫生系统和建立患者信心至关重要。然而,全球存在着适龄儿科配方的短缺,特别是在低收入和中等收入国家。药剂师在确保儿科药物的可得性和正确使用方面至关重要。研究往往忽视了儿科的需求,导致在了解儿童药物可及性方面存在重大差距。因此,本研究试图从阿尔巴尼亚社区药剂师的角度确定获得儿科药物的障碍和促进因素。方法:于2024年3月对阿尔巴尼亚6个人口最多的城市的18名阿尔巴尼亚药剂师进行半结构化访谈。访谈被逐字记录下来,并使用制药价值链框架进行分析。结果:在医药价值链框架的几乎所有领域,获得儿科药物的障碍都很明显,除了卫生信息技术领域,这是一个参与者未提及的领域。所处理的问题包括不同儿童特定诊断的报销清单上数量有限的项目,以及适合儿童的药物偶尔缺货。与其他保健专业人员的开放沟通渠道和对患者的教育被认为是改善获得儿科药品的关键促进因素。结论:这是第一个从社区药师的角度来研究阿尔巴尼亚儿科药物可及性的研究。研究结果提供了针对具体情况的见解,可以为政策改革和卫生系统战略提供信息,以改善儿科药物的公平可得性。
{"title":"'Challenges in pediatric medicine access in Albania: insights from community Pharmacists'.","authors":"E Petro, T Martopullo, A K Mantel-Teeuwisse, H A van den Ham, F Suleman","doi":"10.1080/20523211.2025.2521425","DOIUrl":"10.1080/20523211.2025.2521425","url":null,"abstract":"<p><strong>Background: </strong>Medicines are crucial for strengthening health systems and building patient confidence. Yet, there is a global shortage of age-appropriate pediatric formulations, particularly in low- and middle-income countries. Pharmacists are vital in ensuring pediatric medicines' availability and proper use. Research has often overlooked pediatric needs, resulting in significant gaps in understanding the accessibility of medicines for children. This research therefore sought to identify the barriers and facilitators to accessing pediatric medicines from the perspective of community pharmacists in Albania.</p><p><strong>Methods: </strong>Semi-structured interviews were conducted in March 2024 with 18 members of the Albanian Order of Pharmacists, working in the six most populated cities in Albania. Interviews were transcribed verbatim and analyzed using the Pharmaceutical Value Chain framework.</p><p><strong>Results: </strong>Barriers to accessing pediatric medicines were evident in almost all domains of the Pharmaceutical Value Chain framework except for health information technology, a domain not referred to by participants. Issues addressed included a limited number of items on the reimbursement list for different child-specific diagnoses and occasional stock-outs of child-appropriate medicines. Open communication channels with other healthcare professionals and patient education were identified as key facilitators in improving access to pediatric medicines.</p><p><strong>Conclusion: </strong>This is the first study to examine pediatric medicine access in Albania from the viewpoint of community pharmacists. The findings provide context-specific insights that can inform policy reforms and health system strategies to improve the equitable availability of pediatric medicines.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2521425"},"PeriodicalIF":3.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The patient 'must find his own way': public policies concerning access to medicines in Angola. 病人“必须找到自己的路”:安哥拉关于获得药物的公共政策。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2521429
Elisa Dulce João Fundanga Calipi, Fernanda Manzini, Leandro Ribeiro Molina, Silvana Nair Leite

Background: This study analyses public policies concerning access to medicines and pharmaceutical services in Angola from the right to health perspective. Angola, located in the Western Region of Southern Africa, gained independence in 1975, but the regulation of pharmaceutical activity was enacted only in 2010. Despite these policies, health policies alone do not guarantee the right to health.

Methods: This qualitative research involves documentary analysis, participant observation, and interviews, utilising theoretical frameworks on access to medicines, health systems, and sociotechnical systems. The analysis framework is organised into three domains: legal rights and obligations, good governance, and service implementation. Data from documentary analysis and field research were categorised within these domains.

Results: The findings indicate that the regulatory framework acts as a 'letter of intent', as legal guarantees are vague and lack clarity regarding responsibilities and resource allocation. Additional weaknesses include indecipherable financing, centralised management, cultural barriers, lack of transparency, and limited recognition of the right to access medicines among health professionals. These issues are further exacerbated by Angola's political-economic structure, external dependence on medicines, and insufficiently trained human resources.

Conclusion: To enhance access to necessary medicines and services, investment in the education of health professionals and training for community leaders is essential. Public policies regarding access to medicines in Angola are still incipient; therefore, improving drug policy and pharmaceutical services is crucial to ensure access within the framework of the right to comprehensive health care.

背景:本研究从健康权的角度分析了安哥拉有关获得药品和医药服务的公共政策。安哥拉位于南部非洲西部地区,1975年获得独立,但直到2010年才颁布了对药品活动的监管。尽管有这些政策,但仅靠卫生政策并不能保障健康权。方法:这一定性研究涉及文献分析、参与性观察和访谈,利用关于获得药物、卫生系统和社会技术系统的理论框架。分析框架被组织成三个领域:法律权利和义务、良好治理和服务实现。来自文献分析和实地研究的数据被归类在这些领域内。结果:研究结果表明,监管框架的作用是“意向书”,因为法律保障是模糊的,缺乏明确的责任和资源分配。其他弱点包括难以理解的融资、集中管理、文化障碍、缺乏透明度以及卫生专业人员对获得药品权利的有限承认。安哥拉的政治经济结构、对外依赖药品和训练不足的人力资源进一步加剧了这些问题。结论:为了增加获得必要药品和服务的机会,必须投资于卫生专业人员的教育和社区领导人的培训。安哥拉关于获得药品的公共政策仍处于起步阶段;因此,改善药物政策和药品服务对于确保在全面保健权的框架内获得服务至关重要。
{"title":"The patient 'must find his own way': public policies concerning access to medicines in Angola.","authors":"Elisa Dulce João Fundanga Calipi, Fernanda Manzini, Leandro Ribeiro Molina, Silvana Nair Leite","doi":"10.1080/20523211.2025.2521429","DOIUrl":"10.1080/20523211.2025.2521429","url":null,"abstract":"<p><strong>Background: </strong>This study analyses public policies concerning access to medicines and pharmaceutical services in Angola from the right to health perspective. Angola, located in the Western Region of Southern Africa, gained independence in 1975, but the regulation of pharmaceutical activity was enacted only in 2010. Despite these policies, health policies alone do not guarantee the right to health.</p><p><strong>Methods: </strong>This qualitative research involves documentary analysis, participant observation, and interviews, utilising theoretical frameworks on access to medicines, health systems, and sociotechnical systems. The analysis framework is organised into three domains: legal rights and obligations, good governance, and service implementation. Data from documentary analysis and field research were categorised within these domains.</p><p><strong>Results: </strong>The findings indicate that the regulatory framework acts as a 'letter of intent', as legal guarantees are vague and lack clarity regarding responsibilities and resource allocation. Additional weaknesses include indecipherable financing, centralised management, cultural barriers, lack of transparency, and limited recognition of the right to access medicines among health professionals. These issues are further exacerbated by Angola's political-economic structure, external dependence on medicines, and insufficiently trained human resources.</p><p><strong>Conclusion: </strong>To enhance access to necessary medicines and services, investment in the education of health professionals and training for community leaders is essential. Public policies regarding access to medicines in Angola are still incipient; therefore, improving drug policy and pharmaceutical services is crucial to ensure access within the framework of the right to comprehensive health care.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2521429"},"PeriodicalIF":3.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating pharmaceutical product recalls due to discolouration: a Kenyan case review (January 2016-December 2024). 调查因变色引起的药品召回:肯尼亚案例回顾(2016年1月- 2024年12月)。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2522314
L J Tirop

Product discolouration is a visually detectable quality defect that can undermine patient trust, often leading to non-adherence due to fears of contamination or chemical degradation. A retrospective study of product recalls due to discolouration, within Kenya, between January 2016 and December 2024 was conducted. Study data was extracted from the Pharmacy and Poisons Board online database, which forms a repository of all product recalls and rapid/safety alerts. All recall entries due to product discolouration were included in the study. A total of 36 products were recalled due to discolouration during the study period, with the number of recalls varying from none to 9 products per year. Tablets constituted 55.6% of the recalled products. A total of 38.9% of the products were anti-infectives. This is a notable concern, as abrupt disruption of anti-infective treatment and/or substandard products can drive drug resistance. Generic formulations comprised 97.2% of recalled products. Twenty-one industries were involved in the manufacture of recalled products, with six industries being affected by multiple recalls. Products locally manufactured in Kenya accounted for 63.9% of the recalls. A comprehensive discussion of the probable causes of the observed discolouration, guided by use of the fishbone (Ishikawa) diagram, revealed three sub-themes namely chemical reactions: microbiological and physical contamination. Product recalls due to discolouration proved to be an emerging concern, affecting up to 70 batches of a product in some cases. The in-depth discussion provides guidance on conducting investigations to identify the root cause of observed defects. The adoption of the fishbone tool alongside development of structured forms for defect reporting and quality assurance workflows is recommended.

产品变色是一种可以通过视觉检测到的质量缺陷,它会破坏患者的信任,通常由于担心污染或化学降解而导致不依从性。对2016年1月至2024年12月期间肯尼亚境内因变色而召回的产品进行了回顾性研究。研究数据来自药房和毒物委员会的在线数据库,该数据库形成了所有产品召回和快速/安全警报的存储库。所有因产品变色而召回的条目都包含在研究中。在研究期间,共有36种产品因变色而被召回,召回数量从每年1种到9种不等。片剂占召回产品的55.6%。共38.9%的产品为抗感染产品。这是一个值得关注的问题,因为抗感染治疗的突然中断和/或不合格产品可能导致耐药性。通用配方占召回产品的97.2%。21个行业涉及召回产品的生产,6个行业受到多次召回的影响。肯尼亚当地生产的产品占召回产品的63.9%。在鱼骨(石川)图的指导下,对观察到的变色的可能原因进行了全面的讨论,揭示了三个子主题,即化学反应:微生物和物理污染。由于变色导致的产品召回被证明是一个新出现的问题,在某些情况下影响多达70批次的产品。深入的讨论为进行调查以确定观察到的缺陷的根本原因提供了指导。建议采用鱼骨工具,同时为缺陷报告和质量保证工作流程开发结构化表单。
{"title":"Investigating pharmaceutical product recalls due to discolouration: a Kenyan case review (January 2016-December 2024).","authors":"L J Tirop","doi":"10.1080/20523211.2025.2522314","DOIUrl":"10.1080/20523211.2025.2522314","url":null,"abstract":"<p><p>Product discolouration is a visually detectable quality defect that can undermine patient trust, often leading to non-adherence due to fears of contamination or chemical degradation. A retrospective study of product recalls due to discolouration, within Kenya, between January 2016 and December 2024 was conducted. Study data was extracted from the Pharmacy and Poisons Board online database, which forms a repository of all product recalls and rapid/safety alerts. All recall entries due to product discolouration were included in the study. A total of 36 products were recalled due to discolouration during the study period, with the number of recalls varying from none to 9 products per year. Tablets constituted 55.6% of the recalled products. A total of 38.9% of the products were anti-infectives. This is a notable concern, as abrupt disruption of anti-infective treatment and/or substandard products can drive drug resistance. Generic formulations comprised 97.2% of recalled products. Twenty-one industries were involved in the manufacture of recalled products, with six industries being affected by multiple recalls. Products locally manufactured in Kenya accounted for 63.9% of the recalls. A comprehensive discussion of the probable causes of the observed discolouration, guided by use of the fishbone (Ishikawa) diagram, revealed three sub-themes namely chemical reactions: microbiological and physical contamination. Product recalls due to discolouration proved to be an emerging concern, affecting up to 70 batches of a product in some cases. The in-depth discussion provides guidance on conducting investigations to identify the root cause of observed defects. The adoption of the fishbone tool alongside development of structured forms for defect reporting and quality assurance workflows is recommended.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2522314"},"PeriodicalIF":3.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia. 在纸上;在实践中:在印度尼西亚对基本药物进行的一项大型实地研究中衡量对官方定价政策的遵守情况。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2521434
Ayu Rahmawati, H U Ramadaniati, Y Anggriani, W Nathanial, E Pisani

Background: In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers' profit.

Methods: Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer's selling price and product's MRP. We also sourced product's list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers' profit by taking into account the profit margin and sales volume.

Results: Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6-7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1-1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions.

Conclusion: The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.

背景:2015年,印度尼西亚卫生部(MoH)颁布了一项法令,通过提供透明价格来确保药品的可负担性,该法令要求所有制造商在药品初级包装上印刷最高零售价格。我们衡量制造商和零售商对法令规定的遵守情况,并估计零售商的利润。方法:从印度尼西亚随机选择的卫生机构、零售药店和网上销售网点购买五种基本药物(别嘌呤醇、氨氯地平、阿莫西林、头孢克肟、地塞米松)。我们记录零售商的销售价格和产品的MRP。我们还从医药市场数据中获取了产品的标价和销量。我们通过评估三个指标(零售价格透明度、允许MRP和允许销售价格)进行MRP政策实施分析。我们还通过考虑利润率和销售量来估算零售商的利润。结果:在1249种样品中,几乎所有样品(99.4%)的包装上都有可见的MRP,透明度高。对于非品牌仿制药,没有一个符合允许MRP,打印MRP与允许MRP的中位数比值为3.5 (IQR为2.6-7.9),而品牌仿制药的符合性更高(11.2%)(IQR为1.1-1.7,中位数为1.1)。33%的样品以高于印刷MRP的价格出售,与医院记录的实际销售价格的一致性最低。在所有研究药物中,品牌仿制药占产品价值的79%,比无品牌仿制药产生更多的利润。结论:通过打印MRP实现透明度和遵守允许的销售价格法规有助于零售商问责。限制非品牌仿制药允许mrp的规定从一开始就不合理,而它们从未对品牌药的价格设定任何限制。这表明没有足够的证据表明该政策有助于其确保负担能力的目标。
{"title":"On paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia.","authors":"Ayu Rahmawati, H U Ramadaniati, Y Anggriani, W Nathanial, E Pisani","doi":"10.1080/20523211.2025.2521434","DOIUrl":"10.1080/20523211.2025.2521434","url":null,"abstract":"<p><strong>Background: </strong>In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers' profit.</p><p><strong>Methods: </strong>Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer's selling price and product's MRP. We also sourced product's list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers' profit by taking into account the profit margin and sales volume.</p><p><strong>Results: </strong>Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6-7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1-1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions.</p><p><strong>Conclusion: </strong>The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2521434"},"PeriodicalIF":3.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolution of medication delivery via drones: revolutionizing healthcare logistics. 无人机药物递送的演变:医疗物流的革命。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-30 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2519137
Ammar A Jairoun, Sabaa S Al-Hemyari, Moyad Shahwan, Abeer M Al-Ghananeem, Faris El-Dahiyat, Sondos Al-Salmi, Zaheer-Ud-Din Babar
{"title":"The evolution of medication delivery via drones: revolutionizing healthcare logistics.","authors":"Ammar A Jairoun, Sabaa S Al-Hemyari, Moyad Shahwan, Abeer M Al-Ghananeem, Faris El-Dahiyat, Sondos Al-Salmi, Zaheer-Ud-Din Babar","doi":"10.1080/20523211.2025.2519137","DOIUrl":"https://doi.org/10.1080/20523211.2025.2519137","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2519137"},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative assessment of rational use of drugs in public and private hospital pharmacies: a multicenter cross-sectional study using INRUD/WHO prescribing indicators. 公立和私立医院药房合理用药的比较评估:使用INRUD/WHO处方指标的多中心横断面研究
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-30 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2519140
Adil A Mahmoud, Asim Ahmed Elnour, Ali Awadallah Saeed, Vineetha Menon, Shereen A M Elhag, Omkalthoum Fathi G, Mohamed Ayoup M, Hussam Abdulhadi M A, Ahmed Sameer E, Mohamed Tahaa E, Semira Abdi Beshir, Nadia Al Mazrouei, Sami Fatehi Abdalla, Fahad T Alsulami, Yousef Saeed Alqarni, Abuelnor Mohammed

Background: Specific actions to promote the RUD in public and private hospitals are highly needed. The current study aimed to assess RUD based on World Health Organization (WHO) prescribing indicators in selected public and private hospitals in Khartoum state-Sudan.

Methods: A multicenter cross-sectional study was conducted in six public and three private hospitals. After ethics approval, a consecutive random sample of 2880 patient encounter prescriptions was selected. The IRDP indicates adherence to RUD.

Results: The average number of drugs per patient encounter prescription was 1.7 ± 0.2 and 2.5 ± 0.2 (overall 2.1) in public and private hospitals, respectively. Drugs prescribed generically were 61% (index 0.61) in public hospitals and 24% (index 0.24) in private hospitals. The index of injection prescribing was 0.1 for public and 0.85 for private hospitals. Drugs on the EDL accounted for 94% of prescriptions in public hospitals and 70% in private hospitals. The EDL prescribing index was 0.94 for public and 0.7 for private hospitals. The overall mean IRDP for public and private hospitals was 3.11.

Conclusion: Inadequate prescribing patterns in public and private hospitals significantly deviate from WHO standards across most prescribing indicators. Consequently, public and private hospitals should strive to promote the RUD.

背景:迫切需要在公立和私立医院推广RUD的具体行动。目前的研究旨在根据世界卫生组织(世卫组织)在苏丹喀土穆州选定的公立和私立医院的处方指标评估RUD。方法:在6所公立医院和3所私立医院进行多中心横断面研究。经伦理审批后,连续随机抽取2880例患者就诊处方。IRDP指示对RUD的遵守。结果:公立医院和民营医院患者人均处方药品数量分别为1.7±0.2和2.5±0.2种(总体2.1种)。公立医院仿制药占61%(指数0.61),民营医院仿制药占24%(指数0.24)。公立医院和私立医院的注射处方指数分别为0.1和0.85。EDL上的药物占公立医院处方的94%,私立医院占70%。公立医院EDL处方指数为0.94,私立医院为0.7。公立和私立医院的总体平均IRDP为3.11。结论:公立和私立医院的处方模式不足,在大多数处方指标上明显偏离世卫组织标准。因此,公立医院和私立医院都应努力推广RUD。
{"title":"Comparative assessment of rational use of drugs in public and private hospital pharmacies: a multicenter cross-sectional study using INRUD/WHO prescribing indicators.","authors":"Adil A Mahmoud, Asim Ahmed Elnour, Ali Awadallah Saeed, Vineetha Menon, Shereen A M Elhag, Omkalthoum Fathi G, Mohamed Ayoup M, Hussam Abdulhadi M A, Ahmed Sameer E, Mohamed Tahaa E, Semira Abdi Beshir, Nadia Al Mazrouei, Sami Fatehi Abdalla, Fahad T Alsulami, Yousef Saeed Alqarni, Abuelnor Mohammed","doi":"10.1080/20523211.2025.2519140","DOIUrl":"10.1080/20523211.2025.2519140","url":null,"abstract":"<p><strong>Background: </strong>Specific actions to promote the RUD in public and private hospitals are highly needed. The current study aimed to assess RUD based on World Health Organization (WHO) prescribing indicators in selected public and private hospitals in Khartoum state-Sudan.</p><p><strong>Methods: </strong>A multicenter cross-sectional study was conducted in six public and three private hospitals. After ethics approval, a consecutive random sample of 2880 patient encounter prescriptions was selected. The IRDP indicates adherence to RUD.</p><p><strong>Results: </strong>The average number of drugs per patient encounter prescription was 1.7 ± 0.2 and 2.5 ± 0.2 (overall 2.1) in public and private hospitals, respectively. Drugs prescribed generically were 61% (index 0.61) in public hospitals and 24% (index 0.24) in private hospitals. The index of injection prescribing was 0.1 for public and 0.85 for private hospitals. Drugs on the EDL accounted for 94% of prescriptions in public hospitals and 70% in private hospitals. The EDL prescribing index was 0.94 for public and 0.7 for private hospitals. The overall mean IRDP for public and private hospitals was 3.11.</p><p><strong>Conclusion: </strong>Inadequate prescribing patterns in public and private hospitals significantly deviate from WHO standards across most prescribing indicators. Consequently, public and private hospitals should strive to promote the RUD.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2519140"},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pictogram comprehension and medication-use literacy among undergraduate students: a cross-sectional survey study. 大学生象形文字理解与用药素养的横断面调查研究。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2522312
Kritsanee Saramunee, Bunleu Sungthong, Chatmanee Taengthonglang, Wiraphol Phimarn

Background: Pictograms are widely used in pharmacy practice to enhance patient understanding, especially in contexts where language or health literacy barriers exist. However, limited data are available on the comprehension of United States Pharmacopeia Convention: Drug Information for the Health Care Professional (USP-DI) pictograms among Thai undergraduate students. This study assessed the understanding of USP-DI pictograms and medication-use literacy, and explored factors associated with pictogram comprehension.

Methods: A cross-sectional survey using a structured questionnaire was conducted among 637 university students between August 2023 and April 2024. The Medication Use Literacy Test (MULT) assessed literacy, and the USP-DI pictogram comprehension test evaluated visual understanding. Binary logistic regression was used to identify factors associated with comprehension levels.

Results: Among the 637 participants, the MULT revealed high literacy, with over 90% of questions answered correctly. The mean score for USP-DI pictogram comprehension was 21.82 ± 3.82. Students in health sciences programmes demonstrated the highest proficiency in both tests, followed by those in social sciences and science and technology programmes, with statistically significant differences (P < 0.05). Logistic regression analysis revealed that students aged >20 years had lower pictogram comprehension than younger students (odds ratio [OR] = 0.47; 95% confidence interval [CI]: 0.25-0.88; P = 0.02). Students with a Grade Point Average <3.00/4.00 (OR = 0.55; 95% CI: 0.32-0.96; P = 0.04) and those from non-health science faculties (OR = 0.04; 95% CI: 0.02-0.08; P < 0.001) also showed significantly lower comprehension levels.

Conclusions: This study highlights disparities in pictogram comprehension among Thai undergraduates and affirms the influence of academic discipline, age, and academic performance. The findings support the need for targeted educational strategies to enhance medication-use literacy and pictogram understanding.

背景:象形文字在药学实践中被广泛使用,以提高患者的理解,特别是在语言或健康素养存在障碍的情况下。然而,关于泰国大学生对美国药典公约:卫生保健专业人员药物信息(USP-DI)象形图的理解的数据有限。本研究评估了对USP-DI象形文字的理解和药物使用素养,并探讨了象形文字理解的相关因素。方法:于2023年8月至2024年4月对637名大学生进行了横断面调查,采用结构化问卷。药物使用读写能力测试(MULT)评估读写能力,USP-DI象形文字理解测试评估视觉理解能力。二元逻辑回归用于识别与理解水平相关的因素。结果:在637名参与者中,MULT显示出较高的识字率,超过90%的问题回答正确。USP-DI象形文字理解的平均得分为21.82±3.82。健康科学专业的学生在这两项测试中都表现出最高的熟练程度,其次是社会科学和科学技术专业的学生,差异有统计学意义(P 20岁学生的象形文字理解能力低于年龄较小的学生(优势比[OR] = 0.47;95%置信区间[CI]: 0.25-0.88;p = 0.02)。平均绩点P = 0.04)和来自非健康科学学院的学生(OR = 0.04;95% ci: 0.02-0.08;结论:本研究突出了泰国大学生象形文字理解的差异,并肯定了学科、年龄和学习成绩对象形文字理解的影响。研究结果支持需要有针对性的教育策略,以提高药物使用素养和象形文字的理解。
{"title":"Pictogram comprehension and medication-use literacy among undergraduate students: a cross-sectional survey study.","authors":"Kritsanee Saramunee, Bunleu Sungthong, Chatmanee Taengthonglang, Wiraphol Phimarn","doi":"10.1080/20523211.2025.2522312","DOIUrl":"10.1080/20523211.2025.2522312","url":null,"abstract":"<p><strong>Background: </strong>Pictograms are widely used in pharmacy practice to enhance patient understanding, especially in contexts where language or health literacy barriers exist. However, limited data are available on the comprehension of United States Pharmacopeia Convention: Drug Information for the Health Care Professional (USP-DI) pictograms among Thai undergraduate students. This study assessed the understanding of USP-DI pictograms and medication-use literacy, and explored factors associated with pictogram comprehension.</p><p><strong>Methods: </strong>A cross-sectional survey using a structured questionnaire was conducted among 637 university students between August 2023 and April 2024. The Medication Use Literacy Test (MULT) assessed literacy, and the USP-DI pictogram comprehension test evaluated visual understanding. Binary logistic regression was used to identify factors associated with comprehension levels.</p><p><strong>Results: </strong>Among the 637 participants, the MULT revealed high literacy, with over 90% of questions answered correctly. The mean score for USP-DI pictogram comprehension was 21.82 ± 3.82. Students in health sciences programmes demonstrated the highest proficiency in both tests, followed by those in social sciences and science and technology programmes, with statistically significant differences (<i>P</i> < 0.05). Logistic regression analysis revealed that students aged >20 years had lower pictogram comprehension than younger students (odds ratio [OR] = 0.47; 95% confidence interval [CI]: 0.25-0.88; <i>P</i> = 0.02). Students with a Grade Point Average <3.00/4.00 (OR = 0.55; 95% CI: 0.32-0.96; <i>P</i> = 0.04) and those from non-health science faculties (OR = 0.04; 95% CI: 0.02-0.08; <i>P</i> < 0.001) also showed significantly lower comprehension levels.</p><p><strong>Conclusions: </strong>This study highlights disparities in pictogram comprehension among Thai undergraduates and affirms the influence of academic discipline, age, and academic performance. The findings support the need for targeted educational strategies to enhance medication-use literacy and pictogram understanding.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2522312"},"PeriodicalIF":3.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supervision, performance assessment, and recognition strategy - a quasi-experimental pre-post study of the multipronged interventions to and strengthen medicines management in Nepal. 监督、绩效评估和认可战略——对尼泊尔加强药品管理的多管齐下干预措施的准实验性前后研究
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-19 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2512180
Reekesh Shrestha, Santusta Adhikari, Anup Bastola, Sushil Nepal, Tamara Hafner, Birna Trap

Background: To improve medicines management (MM) in health facilities, Nepal piloted a multipronged intervention - the supervision, performance assessment, and recognition strategy (SPARS). This paper describes a pre-post intervention to assess the SPARS intervention effect on improving MM in selected government health facilities at all levels of care.

Methods: Selected health workers were trained as MM supervisors (MMS) to visit health facilities, assess MM performance, and use the findings to provide support in MM practices. MMS assessed performance using an indicator-based tool containing 25 MM indicators covering five domains: dispensing quality, prescribing quality, stock management, storage management, and ordering and reporting, for a maximum score of 25. From mid-2022 to October 2023, 48 MMS visited 347 government health facilities in 12 randomly selected pilot districts in three provinces. We assessed SPARS indicator performance over 3 supervisory visits.

Results: Between the first and third SPARS visit, we found a significant (p ≤ 0.000) improvement of 123% or a 41.4 percentage-point change in the overall SPARS indicator score from an average of 8.5-18.8. improvements were observed in all five domains. Further, MMS with less than 10 years of experience had a higher impact than more experienced MMS - 39.4 and 33.8 points, respectively. At baseline, no facility had adequate SPARS scores of ≥75%, while 184 facilities (53%) were adequate by the third visit. There was no significant difference in impact measured between provinces; remote and residential facilities; high, medium, and low-level care facilities; and resource-based and behavioural indicators.

Conclusion: Following three supervisory visits, the multipronged intervention significantly improved the overall SPARS score and all 25 indicators assessing performance in stock and storage, ordering and reporting, and dispensing and prescribing quality. We recommend SPARS as an effective approach to strengthen MM in health facilities in Nepal and other low-income countries.

背景:为了改善卫生机构的药品管理,尼泊尔试行了一项多管齐下的干预措施——监督、绩效评估和识别战略(SPARS)。本文描述了一种前后干预,以评估SPARS干预对改善各级政府卫生机构MM的效果。方法:将选定的卫生工作者培训为MM监督员(MMS),以访问卫生机构,评估MM绩效,并利用调查结果为MM实践提供支持。MMS使用基于指标的工具评估绩效,该工具包含25个MM指标,涵盖五个领域:配药质量、处方质量、库存管理、存储管理以及订购和报告,最高得分为25分。从2022年年中到2023年10月,48名MMS在3个省随机选择的12个试点地区访问了347家政府卫生机构。我们在3次监督访问中评估了SPARS指标的表现。结果:在第一次和第三次SPARS就诊之间,我们发现SPARS总体指标得分从平均8.5-18.8分显著改善了123% (p≤0.000)或41.4个百分点的变化。在所有五个领域都观察到改善。此外,经验不足10年的MMS比经验丰富的MMS有更高的影响,分别为39.4分和33.8分。基线时,没有一家医院的SPARS评分≥75%,而第三次就诊时,184家医院(53%)达到了适足。省与省之间的影响没有显著差异;偏远和居住设施;高级、中级和低级护理设施;以及基于资源和行为的指标。结论:经过三次监督访问,多管齐下的干预措施显著提高了SPARS总体评分和库存与储存、订货与报告、调剂与处方质量等25项绩效评估指标。我们建议SPARS作为在尼泊尔和其他低收入国家的卫生设施中加强MM的有效方法。
{"title":"Supervision, performance assessment, and recognition strategy - a quasi-experimental pre-post study of the multipronged interventions to and strengthen medicines management in Nepal.","authors":"Reekesh Shrestha, Santusta Adhikari, Anup Bastola, Sushil Nepal, Tamara Hafner, Birna Trap","doi":"10.1080/20523211.2025.2512180","DOIUrl":"10.1080/20523211.2025.2512180","url":null,"abstract":"<p><strong>Background: </strong>To improve medicines management (MM) in health facilities, Nepal piloted a multipronged intervention - the supervision, performance assessment, and recognition strategy (SPARS). This paper describes a pre-post intervention to assess the SPARS intervention effect on improving MM in selected government health facilities at all levels of care.</p><p><strong>Methods: </strong>Selected health workers were trained as MM supervisors (MMS) to visit health facilities, assess MM performance, and use the findings to provide support in MM practices. MMS assessed performance using an indicator-based tool containing 25 MM indicators covering five domains: dispensing quality, prescribing quality, stock management, storage management, and ordering and reporting, for a maximum score of 25. From mid-2022 to October 2023, 48 MMS visited 347 government health facilities in 12 randomly selected pilot districts in three provinces. We assessed SPARS indicator performance over 3 supervisory visits.</p><p><strong>Results: </strong>Between the first and third SPARS visit, we found a significant (<i>p</i> ≤ 0.000) improvement of 123% or a 41.4 percentage-point change in the overall SPARS indicator score from an average of 8.5-18.8. improvements were observed in all five domains. Further, MMS with less than 10 years of experience had a higher impact than more experienced MMS - 39.4 and 33.8 points, respectively. At baseline, no facility had adequate SPARS scores of ≥75%, while 184 facilities (53%) were adequate by the third visit. There was no significant difference in impact measured between provinces; remote and residential facilities; high, medium, and low-level care facilities; and resource-based and behavioural indicators.</p><p><strong>Conclusion: </strong>Following three supervisory visits, the multipronged intervention significantly improved the overall SPARS score and all 25 indicators assessing performance in stock and storage, ordering and reporting, and dispensing and prescribing quality. We recommend SPARS as an effective approach to strengthen MM in health facilities in Nepal and other low-income countries.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2512180"},"PeriodicalIF":3.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prescribing trends and patterns for antihypertensive agents in primary healthcare settings in Qatar: a retrospective observational study. 卡塔尔初级卫生保健机构抗高血压药物的处方趋势和模式:一项回顾性观察性研究
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2512183
Nada Nabil Abdelkader, Ahmed Awaisu, Hazem Elewa, Ziyad Mahfoud, Samya Ahmad Al Abdulla, Amjad Owais, Maguy Saffouh El Hajj

Background: An observational retrospective study was conducted in the primary care setting in Qatar to evaluate the prescribing trends and patterns of antihypertensives in hypertensive patients.

Methods: Included patients were adult patients (aged ≥18 years) diagnosed with essential hypertension and attending Primary Health Care Corporation (PHCC) clinics in Qatar between January 2017 and March 2021. A sample of 2185 patients was randomly selected. The data were collected from PHCC's electronic medical records system, Cerner©.

Results: Angiotensin Converting Enzyme inhibitors (ACEIs) prescriptions decreased from 38% in 2017 to 21% in 2021, and that of Angiotensin Receptor Blockers (ARBs) from 37% in 2017 to 31% in 2021. Patients with prescribed Calcium Channel Blockers (CCBs) increased from 31% in 2017 to 40% in 2021. The prescribing of thiazide diuretics declined from 32% in 2017 to 9% in 2021. In 2017, the most prescribed antihypertensive class was ACEIs (38%), while the least prescribed antihypertensive class was loop diuretics (1.4%). In 2018, the most prescribed class of antihypertensives was CCBs (36%) and the least prescribed was vasodilators (0.1%). In 2019, 2020 and 2021, CCBs were the most prescribed.

Conclusion: These findings are consistent with national and international guidelines for hypertension management and with published literature. Yet, there is still room for improvement to optimise antihypertensive prescribing practices. Prescribers need to address potential gaps and explore ways to enhance their hypertension management, so that patients have access to effective and evidence-based treatments.

背景:在卡塔尔的初级保健机构进行了一项观察性回顾性研究,以评估高血压患者抗高血压药物的处方趋势和模式。方法:纳入的患者是2017年1月至2021年3月期间在卡塔尔初级卫生保健公司(PHCC)诊所就诊的诊断为原发性高血压的成年患者(年龄≥18岁)。随机抽取2185例患者。数据来自PHCC的电子病历系统Cerner©。结果:血管紧张素转换酶抑制剂(ACEIs)的处方率从2017年的38%下降到2021年的21%,血管紧张素受体阻滞剂(ARBs)的处方率从2017年的37%下降到2021年的31%。服用钙通道阻滞剂(CCBs)的患者从2017年的31%增加到2021年的40%。噻嗪类利尿剂的处方率从2017年的32%下降到2021年的9%。2017年,处方最多的降压药是acei(38%),而处方最少的降压药是利尿剂(1.4%)。2018年,处方最多的抗高血压药物是CCBs(36%),处方最少的是血管扩张剂(0.1%)。2019年、2020年和2021年,建行处方最多。结论:这些发现与国家和国际高血压管理指南以及已发表的文献一致。然而,在优化抗高血压处方实践方面仍有改进的余地。开处方者需要解决潜在的差距,探索加强高血压管理的方法,使患者能够获得有效的循证治疗。
{"title":"Prescribing trends and patterns for antihypertensive agents in primary healthcare settings in Qatar: a retrospective observational study.","authors":"Nada Nabil Abdelkader, Ahmed Awaisu, Hazem Elewa, Ziyad Mahfoud, Samya Ahmad Al Abdulla, Amjad Owais, Maguy Saffouh El Hajj","doi":"10.1080/20523211.2025.2512183","DOIUrl":"10.1080/20523211.2025.2512183","url":null,"abstract":"<p><strong>Background: </strong>An observational retrospective study was conducted in the primary care setting in Qatar to evaluate the prescribing trends and patterns of antihypertensives in hypertensive patients.</p><p><strong>Methods: </strong>Included patients were adult patients (aged ≥18 years) diagnosed with essential hypertension and attending Primary Health Care Corporation (PHCC) clinics in Qatar between January 2017 and March 2021. A sample of 2185 patients was randomly selected. The data were collected from PHCC's electronic medical records system, Cerner©.</p><p><strong>Results: </strong>Angiotensin Converting Enzyme inhibitors (ACEIs) prescriptions decreased from 38% in 2017 to 21% in 2021, and that of Angiotensin Receptor Blockers (ARBs) from 37% in 2017 to 31% in 2021. Patients with prescribed Calcium Channel Blockers (CCBs) increased from 31% in 2017 to 40% in 2021. The prescribing of thiazide diuretics declined from 32% in 2017 to 9% in 2021. In 2017, the most prescribed antihypertensive class was ACEIs (38%), while the least prescribed antihypertensive class was loop diuretics (1.4%). In 2018, the most prescribed class of antihypertensives was CCBs (36%) and the least prescribed was vasodilators (0.1%). In 2019, 2020 and 2021, CCBs were the most prescribed.</p><p><strong>Conclusion: </strong>These findings are consistent with national and international guidelines for hypertension management and with published literature. Yet, there is still room for improvement to optimise antihypertensive prescribing practices. Prescribers need to address potential gaps and explore ways to enhance their hypertension management, so that patients have access to effective and evidence-based treatments.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2512183"},"PeriodicalIF":3.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a contraceptive dispensing protocol for community pharmacists in Qatar: a Delphi study. 卡塔尔社区药剂师避孕配药方案的开发和验证:德尔菲研究。
IF 3.3 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI: 10.1080/20523211.2025.2512186
Haya Monzer Baroudi, Muhammad Abdul Hadi, Bridget Paravattil, Yehia El Khawly, Maguy Saffouh El Hajj

Background: Hormonal contraceptives are available over the counter in community pharmacies in Qatar, placing significant responsibility on community pharmacists (CPs) to ensure safe use. The current study aimed to develop and validate a contraceptive dispensing protocol for CPs use in Qatar.

Methods: A scoping review identified suitable protocols, with an initial protocol adapted from The United States Medical Eligibility Criteria for Contraceptive Use, developed by the Centers for Disease Control and Prevention. Validation occurred through a three-round online Delphi technique: one qualitative round and two quantitative rounds. A panel of ten licensed obstetricians and gynecologists in Qatar participated. Qualitative data were thematically analysed, and consensus in quantitative rounds was defined as over 80% participant agreement.

Results: Two major themes emerged: (1) challenges in assessing the appropriateness of items related to protected intercourse, recent childbirth, and cultural sensitivity around sexually transmitted disease-related questions, and (2) positive feedback on screening and simplification recommendations. In the first round, the protocol comprised 31 items. In the second round, 25 of these items reached consensus. Five items that received 70% to 80% agreement were carried forward to a third round, along with one newly added item. Of the six items assessed in the third round, consensus was achieved for five. Consequently, the final protocol consisted of 29 items.

Conclusion: A 29-item protocol was developed and validated to assess women's eligibility for contraceptive use by CPs in Qatar. Future research should target translating the protocol into other languages and conducting cultural adaptation studies. It should also explore the development and testing of a collaborative intervention involving pharmacists and other healthcare providers to deliver comprehensive, multidisciplinary contraceptive services to patients.

背景:激素避孕药在卡塔尔的社区药店可以在柜台上买到,这给社区药剂师(CPs)带来了重大责任,以确保安全使用。目前的研究旨在制定和验证卡塔尔使用CPs的避孕配药方案。方法:范围审查确定了合适的方案,最初的方案改编自疾病控制和预防中心制定的《美国避孕药具使用医疗资格标准》。通过三轮在线德尔菲技术进行验证:一轮定性和两轮定量。一个由卡塔尔的十位有执照的妇产科医生组成的小组参加了会议。定性数据进行主题分析,定量轮的共识被定义为超过80%的参与者同意。结果:出现了两个主要主题:(1)评估与保护性性交、近期分娩和围绕性传播疾病相关问题的文化敏感性相关项目的适当性方面的挑战;(2)对筛选和简化建议的积极反馈。第一轮议定书共有31个项目。在第二轮谈判中,达成共识的项目有25个。获得70%至80%同意的5个项目和新增加的1个项目将继续进行第三轮谈判。在第三轮审议的6个议题中,有5个议题达成共识。因此,最后议定书有29个项目。结论:制定并验证了一项29项协议,以评估卡塔尔CPs妇女使用避孕药具的资格。未来的研究应着眼于将议定书翻译成其他语言并进行文化适应研究。它还应探索开发和测试一种涉及药剂师和其他保健提供者的协作干预措施,以便向患者提供全面的、多学科的避孕服务。
{"title":"Development and validation of a contraceptive dispensing protocol for community pharmacists in Qatar: a Delphi study.","authors":"Haya Monzer Baroudi, Muhammad Abdul Hadi, Bridget Paravattil, Yehia El Khawly, Maguy Saffouh El Hajj","doi":"10.1080/20523211.2025.2512186","DOIUrl":"10.1080/20523211.2025.2512186","url":null,"abstract":"<p><strong>Background: </strong>Hormonal contraceptives are available over the counter in community pharmacies in Qatar, placing significant responsibility on community pharmacists (CPs) to ensure safe use. The current study aimed to develop and validate a contraceptive dispensing protocol for CPs use in Qatar.</p><p><strong>Methods: </strong>A scoping review identified suitable protocols, with an initial protocol adapted from The United States Medical Eligibility Criteria for Contraceptive Use, developed by the Centers for Disease Control and Prevention. Validation occurred through a three-round online Delphi technique: one qualitative round and two quantitative rounds. A panel of ten licensed obstetricians and gynecologists in Qatar participated. Qualitative data were thematically analysed, and consensus in quantitative rounds was defined as over 80% participant agreement.</p><p><strong>Results: </strong>Two major themes emerged: (1) challenges in assessing the appropriateness of items related to protected intercourse, recent childbirth, and cultural sensitivity around sexually transmitted disease-related questions, and (2) positive feedback on screening and simplification recommendations. In the first round, the protocol comprised 31 items. In the second round, 25 of these items reached consensus. Five items that received 70% to 80% agreement were carried forward to a third round, along with one newly added item. Of the six items assessed in the third round, consensus was achieved for five. Consequently, the final protocol consisted of 29 items.</p><p><strong>Conclusion: </strong>A 29-item protocol was developed and validated to assess women's eligibility for contraceptive use by CPs in Qatar. Future research should target translating the protocol into other languages and conducting cultural adaptation studies. It should also explore the development and testing of a collaborative intervention involving pharmacists and other healthcare providers to deliver comprehensive, multidisciplinary contraceptive services to patients.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2512186"},"PeriodicalIF":3.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Policy and Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1